AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20487485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-provided, community-based teaching of breast self-examination
Number of subjects: 1510
Study 20487485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1510
Study 17545893 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 12 weeks
Number of subjects: 136
Study 17545893 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass model
Number of subjects: 136
Study 17545893 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA model
Number of subjects: 136
Study 17545893 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 136
Study 15708879 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 682
Study 15708879 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 682
Study 12215237 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention group
Number of subjects: 5887
Study 12215237 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 5887
Study 12215237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine verification
Number of subjects: 5887
Study 12215237 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide verification
Number of subjects: 5887
Study 9795924 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN 9 micrograms, three times weekly for 24 weeks
Number of subjects: 0
Study 9795924 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN 15 micrograms, three times weekly for 48 weeks
Number of subjects: 0
Study 9795924 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha‐2b 3 MU administered 3 times per week for 6 to 12 months
Number of subjects: 0
Study 7614541 — intervention group
Group type: EXPERIMENTAL
Intervention: Voda guiding catheter (group 1, n = 50)
Number of subjects: 100
Study 7614541 — intervention group
Group type: COMPARATOR
Intervention: Judkins or Amplatz guiding catheter (group 2, n = 50)
Number of subjects: 100
Study 7614541 — intervention group
Group type: EXPERIMENTAL
Intervention: Voda guiding catheter (group 1)
Number of subjects: 100
Study 2515571 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA (3.0 g/day, in three divided doses) and misoprostol (600 mcg/day, co-administered with ASA)
Number of subjects: 60
Study 2515571 — intervention group
Group type: COMPARATOR
Intervention: ASA and placebo
Number of subjects: 60
Study 327003 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene
Number of subjects: 0
Study 327003 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 327003 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propoxyphene and acetaminophen
Number of subjects: 0
Study 327003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31888977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth beacon technology app activated
Number of subjects: 411
Study 31888977 — intervention group
Group type: COMPARATOR
Intervention: Bluetooth beacon technology app not activated
Number of subjects: 411
Study 31544290 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium fiber laser enucleation of the prostate
Number of subjects: 103
Study 31544290 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate
Number of subjects: 103
Study 30012981 — intervention group
Group type: EXPERIMENTAL
Intervention: NumTrey (locally produced fish-based RUTF)
Number of subjects: 121
Study 30012981 — intervention group
Group type: COMPARATOR
Intervention: BP-100™ (imported milk-based RUTF)
Number of subjects: 121
Study 26499270 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN/RBV
Number of subjects: 192
Study 26499270 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN alone
Number of subjects: 192
Study 26499270 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 192
Study 24138536 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 2 mg
Number of subjects: 302
Study 24138536 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg
Number of subjects: 302
Study 24138536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 22030199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine jet injection (0.2 mL of lidocaine 2%)
Number of subjects: 42
Study 22030199 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 1 mL of lidocaine gel 2% (control)
Number of subjects: 42
Study 19606510 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven‐star Needle Stimulation (30 sessions over 6 weeks, 5 to 10 min per session)
Number of subjects: 32
Study 19606510 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list, no treatment)
Number of subjects: 32
Study 19606510 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven‐star Needle Stimulation
Number of subjects: 32
Study 19606510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 17260315 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light filter IOLs (AF‐1 UY, Hoya, Japan)
Number of subjects: 43
Study 17260315 — intervention group
Group type: COMPARATOR
Intervention: IOLs without blue light filter (AF‐1 UV, Hoya, Japan)
Number of subjects: 43
Study 15029476 — intervention group
Group type: EXPERIMENTAL
Intervention: New pharmacological substances for metaphylaxis
Number of subjects: 0
Study 15029476 — intervention group
Group type: COMPARATOR
Intervention: Established dietary advice
Number of subjects: 0
Study 15029476 — intervention group
Group type: COMPARATOR
Intervention: Good common practice drugs
Number of subjects: 0
Study 11438057 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser photocoagulation
Number of subjects: 10
Study 11438057 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 10
Study 9504953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified liquid milk (500 ml per day)
Number of subjects: 51
Study 9504953 — intervention group
Group type: COMPARATOR
Intervention: Unfortified milk (control group)
Number of subjects: 51
Study 7988193 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide, 800 micrograms
Number of subjects: 14
Study 7988193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2563787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg twice daily
Number of subjects: 30
Study 2563787 — intervention group
Group type: COMPARATOR
Intervention: Control (supine level without ischaemia)
Number of subjects: 30
Study 30899086 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular apocrine (MA) subtype patients receiving neoadjuvant chemotherapy
Number of subjects: 846
Study 30899086 — intervention group
Group type: COMPARATOR
Intervention: Triple-negative (TN) basal-like tumours
Number of subjects: 846
Study 28027226 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge resection of the bony nasal pyramid from the base of the nasal bone
Number of subjects: 166
Study 28027226 — intervention group
Group type: COMPARATOR
Intervention: Oblique hump resection
Number of subjects: 166
Study 28027226 — intervention group
Group type: EXPERIMENTAL
Intervention: Base nasal bone resection
Number of subjects: 166
Study 28027226 — intervention group
Group type: COMPARATOR
Intervention: Different plastic surgeons' evaluations
Number of subjects: 166
Study 25890572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 97
Study 25890572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 24374800 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with endovascular implantation of an iodine-125 seed strand
Number of subjects: 85
Study 24374800 — intervention group
Group type: COMPARATOR
Intervention: Conventional TACE
Number of subjects: 85
Study 22947546 — intervention group
Group type: EXPERIMENTAL
Intervention: Galileo platform (GP) at 22 Hz
Number of subjects: 10
Study 22947546 — intervention group
Group type: COMPARATOR
Intervention: Juvent1000 platform (JP)
Number of subjects: 10
Study 19848196 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI), 60 mL once a day for 10 days each month over a treatment course of 6 months.
Number of subjects: 100
Study 19848196 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (Control group).
Number of subjects: 100
Study 17720642 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous drains
Number of subjects: 250
Study 17720642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drains)
Number of subjects: 250
Study 15750884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 intraocular lens
Number of subjects: 64
Study 15750884 — intervention group
Group type: COMPARATOR
Intervention: Acrysof SA60AT intraocular lens
Number of subjects: 64
Study 11968069 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release formulations of metoprolol (100 mg) with varying release rates (slow, moderate, fast)
Number of subjects: 0
Study 11968069 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of metoprolol (50 mg)
Number of subjects: 0
Study 11968069 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release formulations of metoprolol (100 mg) with fast input
Number of subjects: 0
Study 10365008 — intervention group
Group type: EXPERIMENTAL
Intervention: GR205171 25 mg i.v.
Number of subjects: 36
Study 10365008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7735677 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 23
Study 7735677 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 23
Study 1774544 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C administration (3 grams per day during Weeks 5 to 8)
Number of subjects: 13
Study 1774544 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal delays imposed between successive responses during sequence acquisition
Number of subjects: 13
Study 1774544 — intervention group
Group type: COMPARATOR
Intervention: Control condition with reinstated stimuli correlated with sequence position
Number of subjects: 13
Study 6814610 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (supported) group
Number of subjects: 50
Study 6814610 — intervention group
Group type: COMPARATOR
Intervention: Contrast group (routine hospital care)
Number of subjects: 50
Study 6814610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 6814610 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially isolated women and those with lack of intimacy in marital relations
Number of subjects: 50
Study 6814610 — intervention group
Group type: COMPARATOR
Intervention: Unsupported group
Number of subjects: 50
Study 6814610 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and counselling
Number of subjects: 50
Study 30502933 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 0
Study 30502933 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28297698 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (365 mg of oral magnesium once daily for 3 months)
Number of subjects: 128
Study 28297698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 3 months)
Number of subjects: 128
Study 25028997 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 21
Study 25028997 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 21
Study 23915235 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterfly Girls online program (8-episode animated, interactive comic)
Number of subjects: 390
Study 23915235 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 390
Study 23915235 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 390
Study 20156926 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA023B (1.5 mg)
Number of subjects: 0
Study 20156926 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA023B (10 mg/kg)
Number of subjects: 0
Study 20156926 — intervention group
Group type: COMPARATOR
Intervention: MRK‐409
Number of subjects: 0
Study 18078789 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 0
Study 18078789 — intervention group
Group type: COMPARATOR
Intervention: Control garment (usual netball attire)
Number of subjects: 0
Study 18078789 — intervention group
Group type: COMPARATOR
Intervention: Placebo garment
Number of subjects: 0
Study 17171429 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg/day
Number of subjects: 33
Study 17171429 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate 12.5 mg/day (increased to tolerable maximal dose)
Number of subjects: 33
Study 17171429 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Carvedilol and Metoprolol)
Number of subjects: 33
Study 15765005 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized training of repeated reading of a limited set of 32 training words over a period of up to 25 days
Number of subjects: 20
Study 11572290 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo (OS)
Number of subjects: 15
Study 11572290 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (PB)
Number of subjects: 15
Study 11572290 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single Component (SSC)
Number of subjects: 15
Study 11572290 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo (OS) and Prime & Bond 2.1 (PB)
Number of subjects: 15
Study 9773836 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula with egg phospholipids
Number of subjects: 0
Study 9773836 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 0
Study 7947595 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 8
Study 7947595 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 8
Study 3415546 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate
Number of subjects: 0
Study 3415546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29415258 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1-4 mg/d
Number of subjects: 1072
Study 27530473 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich purple sweet potato beverage (PSP), 177 mg anthocyanins per 125-ml bottle, 3 bottles per day for 8 weeks
Number of subjects: 40
Study 25069476 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants associated with drug reactions (rs1799929 and rs1495741 in NAT2)
Number of subjects: 120
Study 25069476 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants associated with thromboembolism (rs7294, rs9923231 and rs9934438 in VKORC1)
Number of subjects: 120
Study 25069476 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants associated with HIV/AIDS and solid tumors (rs2242046 in SLC28A1)
Number of subjects: 120
Study 22981685 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 336
Study 22981685 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 336
Study 22981685 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 336
Study 21917777 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive cortical stimulation (treatment)
Number of subjects: 191
Study 21917777 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 191
Study 19805747 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 26
Study 19805747 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant
Number of subjects: 26
Study 16671482 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesculap-Miethke GA-Valve (GAV; counterbalancer)
Number of subjects: 54
Study 16671482 — intervention group
Group type: COMPARATOR
Intervention: Aesculap-Miethke Dualswitch-Valve (DSV; switcher)
Number of subjects: 54
Study 15724775 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioral counseling (N=22)
Number of subjects: 60
Study 15724775 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive counseling (N=20)
Number of subjects: 60
Study 15724775 — intervention group
Group type: COMPARATOR
Intervention: Physician advice (N=10)
Number of subjects: 60
Study 11378006 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50, 100, and 200 mg)
Number of subjects: 12
Study 11378006 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25, 50, and 100 mg)
Number of subjects: 12
Study 11378006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9223201 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL 0.5% bupivacaine with 1:200,000 epinephrine and 1 mg preservative-free morphine (group BUP-MORPH)
Number of subjects: 75
Study 9223201 — intervention group
Group type: COMPARATOR
Intervention: 30 mL 0.5% bupivacaine with 1:200,000 epinephrine (group BUP)
Number of subjects: 75
Study 9223201 — intervention group
Group type: COMPARATOR
Intervention: 30 mL normal saline with 1:200,000 epinephrine and 1 mg preservative-free morphine (group MORPH)
Number of subjects: 75
Study 7954233 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary hepatic artery occlusion followed by intraportal infusion of 5‐fluorouracil (5‐FU) and oral allopurinol
Number of subjects: 60
Study 7954233 — intervention group
Group type: COMPARATOR
Intervention: No regional or systemic treatment
Number of subjects: 60
Study 2928654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampon use
Number of subjects: 35
Study 2928654 — intervention group
Group type: COMPARATOR
Intervention: Napkin use
Number of subjects: 35
Study 31724966 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 2 mg/1.5 ml (1.34 mg/ml) prefilled pen for subcutaneous injection
Number of subjects: 140
Study 31724966 — intervention group
Group type: COMPARATOR
Intervention: placebo 1.5 ml, pen-injector for subcutaneous injection
Number of subjects: 140
Study 28403291 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits with instructions
Number of subjects: 32
Study 28403291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 32
Study 26163740 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suctioning system
Number of subjects: 42
Study 26163740 — intervention group
Group type: COMPARATOR
Intervention: Open suctioning system
Number of subjects: 42
Study 23265328 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II (HMII) LVAD support
Number of subjects: 1122
Study 21789679 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus™ (HF)
Number of subjects: 81
Study 21789679 — intervention group
Group type: COMPARATOR
Intervention: Knot tying (KT)
Number of subjects: 81
Study 18679148 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) plus standard therapy
Number of subjects: 50
Study 18679148 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 50
Study 16702897 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 244
Study 16702897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 15381054 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggrenox (2 pills/daily)
Number of subjects: 40
Study 15381054 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (81 mg plus matching placebo/daily)
Number of subjects: 40
Study 11183453 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin ovule (3-day treatment)
Number of subjects: 96
Study 11183453 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole vaginal gel
Number of subjects: 96
Study 8752295 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine rotavirus vaccines
Number of subjects: 5353
Study 8752295 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-based vaccines
Number of subjects: 5353
Study 8752295 — intervention group
Group type: EXPERIMENTAL
Intervention: M37 vaccine
Number of subjects: 5353
Study 8752295 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 5353
Study 8752295 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines with demonstrable immunogenicity
Number of subjects: 5353
Study 1371211 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids plus intravenous cyclophosphamide
Number of subjects: 26
Study 1371211 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 26
Study 6827127 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 19
Study 29908826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial CD34+ cell therapy (5 × 10^4 to 5 × 10^5 cells/kg)
Number of subjects: 269
Study 29908826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 28684776 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation therapy (CCRT)
Number of subjects: 27
Study 28684776 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 27
Study 25889698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 3%
Number of subjects: 31
Study 25889698 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4%
Number of subjects: 31
Study 24687582 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of aerobic training on a cycle ergometer
Number of subjects: 23
Study 22808616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous catheter-guided laser ablation (ICLA)
Number of subjects: 134
Study 22808616 — intervention group
Group type: COMPARATOR
Intervention: Stab avulsion (SA)
Number of subjects: 134
Study 19328438 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 alone
Number of subjects: 1200
Study 19328438 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention alone
Number of subjects: 1200
Study 19328438 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 plus multidomain intervention
Number of subjects: 1200
Study 19328438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200